| Cameron, 2014 |
Retrospective chart review |
1 to 252 |
32.7 (range: 19 to 55) |
104 |
84 |
0 |
Nabilone; powdered form; final dosage range: 0.5–6.0 mg |
N/A |
Antipsychotics, sedative/hypnotics, antidepressants, antiadrenergic, NSAIDs, Acetaminophen, Opioids, Anticonvulsants, cyclobenzaprine, prednisone |
| Chan, 2017 |
Prospective (survey) |
639 |
43.25 (range: 19 to 70) |
588 |
540 |
22.28 |
Various varieties of cannabis; same provider |
N/A |
N/A |
| Drost, 2017 |
Prospective (survey) |
120 |
N/A |
647 |
Not clear |
N/A |
Various varieties of cannabis; Indica-dominant or leaning, Sativa dominant or leaning |
NA |
N/A |
| Elms, 2019 |
Retrospective (case series) |
56 |
39.91 (17.39) |
21 |
11 |
73 |
Cannabidiol (CBD); oral capsule or liquid spray; mean total dosage: 33.18 mg-48.64 mg |
N/A |
Anticonvulsant, antidepressant, antipsychotic, anxiolytic/sedative, beta-blocker; dietary changes, herbal supplementation, neurofeedback, and intravenous infusions of vitamins and minerals |
| Greer, 2014 |
Retrospective (chart review) |
N/A |
N/A |
80 |
80 |
N/A |
Various varieties of cannabis |
No-cannabis control |
N/A |
| Jetly, 2015 |
RCT (cross-over) |
49 |
43.6 (8.2) |
10 |
9 |
0 |
Nabilone; Cesamet & Valeant Canada tablets; dosage range: 0.5–3.0 mg |
Matching placebo; Waitlist control |
Antidepressants |
| Johnson, 2016 |
cross-sectional |
N/A |
47.1 |
700 |
700 |
9 |
Various varieties of cannabis |
Case-matched non-users' control |
N/A |
| Roitman, 2014 |
Prospective (open-label, preliminary) |
21 |
52.3 (8.3) |
10 |
10 |
30 |
THC; Dosage range of 2.5–5.0 mg THC in olive oil taken orally; twice daily |
N/A |
Psychopharmacological medications |
| Ruglass, 2017 |
Retrospective |
98 |
Users: 41.63 (9.38), Non-Users: 44 (9.18) |
136 |
136 |
52.21 |
Various varieties of cannabis; self-reported frequency |
Non-users' control |
Sertraline, riboflavin (for adherence) |
| Smith, 2017 |
Retrospective (chart audit) |
N/A |
43 |
100 |
100 |
3 |
Various varieties of cannabis; dosage range of <5, 5-9, 10, & 10 < grams |
N/A |
Medications for pain, depression, anti-psychotic, bipolar disorder, anxiety, ADHD, seizures, muscle relaxants, nightmares, sleep, and related effects, such as erectile dysfunction and nausea |
| Wilkinson, 2015 |
Prospective |
112 |
51.7 (8.6) |
2276 |
2036 |
3.3 |
Various varieties of cannabis |
Cannabis use “stoppers”, “continuing users”, “starters”, & “non-users” |
N/A |
